반응식
N1CCC(O[CH2:8][C:9]2[O:13][N:12]=[C:11]([C:14]3[CH:19]=[CH:18][N:17]=[CH:16][CH:15]=3)[N:10]=2)CC1.[CH:20]1([CH2:25][C:26](Cl)=[O:27])[CH2:24][CH2:23][CH2:22][CH2:21]1>>[CH:20]1([CH2:25][C:26]([N:10]2[CH2:11][CH2:14][CH:8]([C:9]3[O:13][N:12]=[C:11]([C:14]4[CH:15]=[CH:16][N:17]=[CH:18][CH:19]=4)[N:10]=3)[CH2:8][CH2:9]2)=[O:27])[CH2:24][CH2:23][CH2:22][CH2:21]1참가 물질
3
실험 절차
4-[5-(Piperidin-4-yloxymethyl)-[1,2,4]oxadiazol-3-yl]pyridine (Example 51) was reacted with cyclopentylacetyl chloride, in a similar manner to that described in Example 55, to afford the title compound: RT=3.44 min, m/z (ES+)=341.3 [M+H]+.
출처 및 근거
- ORD 기록
- ord-a616ccc788074adca47bb0f078ad85bb
- 출처 데이터셋
- uspto-grants-2012_06
- 특허 번호
- US08207147B2
연결된 노트
불러오는 중…